Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders’ Equity Requirement and Continued Listing on The Nasdaq Stock Market
BOSTON, Jan. 31, 2024 (GLOBE NEWSWIRE) — TransCode Therapeutics, Inc. (Nasdaq:RNAZ), (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it has received notice from the NASDAQ Stock Market LLC (Nasdaq) that the Nasdaq has determined that the Company has regained compliance with the minimum stockholders’ equity requirement under Nasdaq Listing Rule 5550(b)(1) (the Equity Rule) for continued listing on the Nasdaq Capital Market. Pursuant to Nasdaq Listing Rule 5815(d)(4)(B), the Company will be subject to a mandatory panel monitor through January 26, 2025.
Related news for (RNAZ)
- TransCode Therapeutics presents preliminary data from its completed Phase 1a study with TTX-MC138 in metastatic disease at ESMO
- 24/7 Market News Snapshot 08 October, 2025 – TransCode Therapeutics, Inc. Common Stock (NASDAQ:RNAZ)
- Morning Market Brief: Biotech Names Stir as VENU Rockets on FireSuite Sales
- Today’s Top Performers: MoBot’s Market Review 10/08/25 09:00 AM
- TransCode Therapeutics (RNAZ) announces the acquisition of Polynoma and a $25 Million strategic financing by a subsidiary of CK Life Sciences to form a first-in-class unique immuno-oncology and metastatic prevention oncology company